WOLFRAM RESOURCES PLC
("Wolfram" or the "Company")
Proposed Acquisition of Ellipses Pharma Limited
18 November 2026
Further to the announcement on 16 November 2026, Wolfram Resources Plc (LSE: WFR), the Main Market listed special purpose acquisition company whose ordinary shares are traded on the Equity Shares (Shell Companies) listing category, is pleased to announce that it has signed a non-binding Memorandum of Understanding ("MoU") with Ellipses Pharma Limited ("Ellipses"), the London-based oncology drug development company, in respect of the proposed acquisition of the entire issued share capital of Ellipses (the "Proposed Acquisition") and the re-listing of the enlarged group on the Main Market in the Equity Shares (Commercial Companies) category (the “Proposed Relisting”).
If completed, the Proposed Acquisition would give the Company and its shareholders exposure to a portfolio of clinical and near-clinical oncology assets with an attractive growth profile, while providing Ellipses with a public markets platform and access to additional capital to support the continued development of its pipeline.
Highlights
About Ellipses Pharma
Ellipses Pharma is a London-headquartered drug development company focused exclusively on cancer. Founded in 2017 by Professor Sir Chris Evans OBE, Ellipses sources candidate assets globally, selects them through independent expert review utilising its global Scientific Advisory Group and advances them through clinical development. The Scientific Advisory Group was established by Ellipses and includes more than 300 leading oncology experts, across multiple tumour types and therapeutic modalities.
Its portfolio spans multiple clinical-stage programmes, with trial sites across the United States, Europe and Asia Pacific. This includes EP0031 (lunbotinib), a next-generation selective RET inhibitor in Phase 2 development for RET-altered non-small cell lung cancer, partnered with Kelun-Biotech, and EP0062 (vosilasarm), an oral selective androgen receptor modulator in Phase 2 development in ER+/HER2- breast cancer. Further information is available at www.ellipses.life.
Professor Sir Chris Evans OBE, Chair and Founder of Ellipses Pharma Limited, said:
"Our company has been focused resolutely on the development of promising drug candidates and the progress made with our pipeline, including encouraging results from our clinical trials for both EP0031 and EP0062, indicates that this is now an optimal time to move towards a public listing. The transaction with Wolfram will accelerate Ellipses’ plan to deliver the next stage of its evolution as a public company. The ability also to raise additional capital from public company investors will drive the continued growth of our portfolio and enable our current shareholders to realise that growth in the longer term. We look forward to working with the Wolfram team to deliver the transaction."
Graeme Muir, Executive Director of Wolfram Resources Plc, said:
"We are excited to be working with such a strong management team that brings with it years of experience and a proven track record. We now move to detailed due diligence, and we believe this transaction can deliver real value for Wolfram shareholders."
Appointment of Sponsor and Financial Adviser
The Company has appointed Joh. Berenberg, Gossler & Co. KG, London Branch ("Berenberg") as Sponsor and Financial Adviser in respect of the Proposed Transaction.
Conditions
The Proposed Transaction will be conditional on, among other things, satisfactory technical, financial and legal due diligence, agreement of final terms and definitive documentation, the approval by the Financial Conduct Authority (“FCA”) of, and publication by the Company of, a prospectus relating to the enlarged group, shareholder approval, appropriate approval by the Panel on Takeovers and Mergers in relation to a Rule 9 Waiver, and admission of the enlarged issued share capital to the Official List (ESCC category) and to the Main Market.
Inside Information
This announcement contains information which, prior to its disclosure, was inside information for the purpose of the Market Abuse Regulation (as in force in the United Kingdom). The person responsible for arranging the release of this announcement on behalf of Wolfram is Graeme Muir.
- ENDS -
Enquiries:
|
Wolfram Resources Plc |
|
|
Graeme Muir, Executive Director |
gmuir@wolframresources.com |
|
|
www.wolframresources.com |
|
|
|
|
Berenberg |
+44 (0)20 3207 7800 |
|
Sponsor & Financial Adviser |
|
|
|
|
|
AlbR Capital Limited |
+44 (0)20 7469 0930 |
|
Corporate Broker |
|
|
|
|
|
|
|
Important notices
As the commercial terms of the Proposed Acquisition have not yet been agreed, there can be no certainty that the Proposed Transaction will proceed, nor as to the terms on which it may proceed. Shareholders should not place undue reliance on this announcement.
The Company will make further announcements in relation to the Proposed Acquisition as appropriate in accordance with its obligations under the UK Market Abuse Regulation, the Disclosure Guidance and Transparency Rules and once the relevant terms have been agreed will make further announcements providing additional details pursuant to UKLR 13.4.22R and UKLR 13.4.23R.
Joh. Berenberg, Gossler & Co. KG, London Branch, which is authorised and regulated by the German Federal Financial Supervisory Authority and in the United Kingdom is subject to limited regulation by the FCA, is acting exclusively for the Company as Sponsor and Financial Adviser and for no one else in connection with the Proposed Transaction and it will not regard any other person as a client in relation to the Proposed Transaction and will not be responsible to anyone other than the Company for providing the protections afforded to its clients or for providing advice in relation to the Proposed Transaction or any other transaction, matter, or arrangement referred to in this announcement.
This announcement does not constitute an offer of securities for sale in the United States or elsewhere. Wolfram's ordinary shares referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and if the Proposed Transaction proceeds, the ordinary shares will not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act.